Jundishapur Journal of Health Sciences

Published by: Kowsar

Association Between HLA-A*02 Genotype and Multiple Sclerosis in Khuzestan Province, Iran

Roya Ghanavati 1 , 2 , Mohammad Shafiei 1 , 2 , * and Hamid Galehdari 1 , 2
Authors Information
1 Department of Genetics, Faculty of Science, Shahid Chamran University of Ahvaz, Ahvaz, Iran
2 Biotechnology and Bioscience Research Center, Shahid Chamran University of Ahvaz, Ahvaz, Iran
Article information
  • Jundishapur Journal of Health Sciences: April 2018, 10 (2); e59769
  • Published Online: February 7, 2018
  • Article Type: Research Article
  • Received: August 8, 2017
  • Revised: November 12, 2017
  • Accepted: November 13, 2017
  • DOI: 10.5812/jjhs.59769

To Cite: Ghanavati R, Shafiei M, Galehdari H. Association Between HLA-A*02 Genotype and Multiple Sclerosis in Khuzestan Province, Iran, Jundishapur J Health Sci. 2018 ; 10(2):e59769. doi: 10.5812/jjhs.59769.

Copyright © 2018, Jundishapur Journal of Health Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited
1. Background
2. Methods
3. Results
4. Discussion
  • 1. Zuvicha R, McCauleyb JL, Pericak-Vanceb MA. Genetics and pathogenesis of multiple sclerosis. Seminars Immunol. 2009;21:328-33.
  • 2. Compston A, Coles A. Multiple sclerosis. Lancet. 2008;372(9648):1502-17. doi: 10.1016/S0140-6736(08)61620-7. [PubMed: 18970977].
  • 3. Compston A, Coles A. Multiple sclerosis. Lancet. 2002;359(9313):1221-31. doi: 10.1016/S0140-6736(02)08220-X. [PubMed: 11955556].
  • 4. Roxburgh RHSR, Seaman SR, Masterman T, Hensiek AE, Sawcer SJ, Vukusic S, et al. Multiple Sclerosis Severity Score Using disability and disease duration to rate disease severity. Neurology. 2005;64(7):1144-51.
  • 5. Kurtzke JF. Epidemiologic contributions to multiple sclerosis: an overview. Neurology. 1980;30(7 Pt 2):61-79. [PubMed: 6993993].
  • 6. Kurtzke JF. A reassessment of the distribution of multiple sclerosis. Acta Neurol Scand. 1975;51(2):137-57. [PubMed: 1114878].
  • 7. Benamer HT, Ahmed ES, Al-Din AS, Grosset DG. Frequency and clinical patterns of multiple sclerosis in Arab countries: a systematic review. J Neurol Sci. 2009;278(1-2):1-4. doi: 10.1016/j.jns.2008.12.001. [PubMed: 19135686].
  • 8. Weiner HL, Stankiewicz JM. Multiple sclerosis: Diagnosis and therapy. John Wiley & Sons; 2012.
  • 9. Multiple sclerosis Trust. Multiple sclerosis information for health and social care professionals (fourth edition). Hertfordshire: Multiple sclerosis Trust; 2011.
  • 10. Hauser SL, Goodin DS. Harrison's Principles of Internal Medicine. 17th ed. Volumes I and II. Multiple sclerosis and other demyelinating diseases (chapter 380). In: Fauci AS, Braunwald E, Kasper DL, editors. New York: The McGraw-Hill Companies, Inc; 2008. p. 2611-4.
  • 11. Multiple Sclerosis International Federation. Atlas of MS. 2013.
  • 12. Etemadifar M, Janghorbani M, Shaygannejad V, Ashtari F. Prevalence of multiple sclerosis in Isfahan, Iran. Neuroepidemiology. 2006;27(1):39-44. doi: 10.1159/000094235. [PubMed: 16804333].
  • 13. Izadi S, Nikseresht A, Sharifian M, Sahraian MA, Hamidian Jahromi A, Aghighi M, et al. Significant increase in the prevalence of multiple sclerosis in iran in 2011. Iran J Med Sci. 2014;39(2):152-3. [PubMed: 24644387].
  • 14. Radmehr M, Meghdadi S, Bahmanzadeh M, Sabbagh S. Prevalence, Demographics and Clinical Characteristics of Multiple Sclerosis in North of Khuzestan Province, Iran. Jentashapir J Health Res. 2015;6(5). doi: 10.17795/jjhr-23831.
  • 15. Sharafaddinzadeh N, Moghtaderi A, Majdinasab N, Dahmardeh M, Kashipazha D, Shalbafan B. The influence of ethnicity on the characteristics of multiple sclerosis: a local population study between Persians and Arabs. Clin Neurol Neurosurg. 2013;115(8):1271-5. doi: 10.1016/j.clineuro.2012.11.027. [PubMed: 23273383].
  • 16. Samkoff LM, Goodman AD. Symptomatic management in multiple sclerosis. Neurol Clin. 2011;29(2):449-63. doi: 10.1016/j.ncl.2011.01.008. [PubMed: 21439453].
  • 17. The National Collaborating Centre for Chronic conditions. Multiple Sclerosis: National clinical guideline for diagnosis and management in primary and secondary care. 2004. Available from: http://www.nice.org.uk/nicemedia/live/10930/46699/46699.
  • 18. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33(11):1444-52. [PubMed: 6685237].
  • 19. Jafari N, Broer L, Hoppenbrouwers IA, van Duijn CM, Hintzen RQ. Infectious mononucleosis-linked HLA class I single nucleotide polymorphism is associated with multiple sclerosis. Mult Scler. 2010;16(11):1303-7. doi: 10.1177/1352458510376778. [PubMed: 20736246].
  • 20. Hawkes CH, Macgregor AJ. Twin studies and the heritability of MS: a conclusion. Multiple Sclerosis J. 2009;15(6):661-7.
  • 21. Oksenberg JR, Baranzini SE, Sawcer S, Hauser S. The genetics of multiple sclerosis: SNPs to pathways to pathogenesis. Nat Rev Genetics. 2008;9(7):516.
  • 22. Hoffjan Sand Akkad D. The genetics of multiple sclerosis: An update. Molecular and Cellular Probes. 2010.
  • 23. Gourraud PA, Harbo HF, Hauser SL, Baranzini SE. The genetics of multiple sclerosis: an up-to-date review. Immunol Rev. 2012;248(1):87-103. doi: 10.1111/j.1600-065X.2012.01134.x. [PubMed: 22725956].
  • 24. Fernando MMA, Stevens CR, Walsh EC, De Jager PL, Goyette P, Plenge RM, et al. Defining the role of the MHC in autoimmunity: a review and pooled analysis. PLoS Gene. 2008;4(4). e1000024.
  • 25. Travers P, Walport M, Capra JD. Immunobiology: the immune system in health and disease. Current Biology Ltd. 1999.
  • 26. Volanakis JE, Zhu ZB, Schaffer FM, Macon KJ, Palermos J, Barger BO, et al. Major histocompatibility complex class III genes and susceptibility to immunoglobulin A deficiency and common variable immunodeficiency. J Clin Invest. 1992;89(6):1914-22. doi: 10.1172/JCI115797. [PubMed: 1351062].
  • 27. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001;50(1):121-7. [PubMed: 11456302].
  • 28. Pakdehi T, Shafiei M, Galehdari H. HLA DRB5* 01 Association Survey with Multiple Sclerosis in Khuzestan Province of Iran. Zahedan J Res Med Sci. 2017;19(8).
  • 29. Zabihi R, Galehdari H, Shafiee M, Kazeminejad SR, Alavi SM. Analysis of HLA-DQB1*0602 in Multiple Sclerosis Patients in Khuzestan Province, Iran. Arch Iran Med. 2015;18(10):698-702. [PubMed: 26443252].
  • 30. Delfan N, Galehdari H, Kazeminejad SR, Shafiei M, Zabihi R, Majdinasab N. Analysis of HLA-DRB1*1501 in Multiple Sclerosis Patients in Khuzestan Province, Iran. Zahedan J Res Med Sci. 2017;19(3). doi: 10.5812/zjrms.5647.
  • 31. Rosati G. The prevalence of multiple sclerosis in the world: an update. Neurol Sci. 2001;22(2):117-39. [PubMed: 11603614].
  • 32. Moreira MA, Felipe E, Mendes MF, Tilbery CP. [Multiple sclerosis: descriptive study of its clinical forms in 302 cases]. Arq Neuropsiquiatr. 2000;58(2B):460-6. [PubMed: 10920407].
  • 33. Kalanie H, Gharagozli K, Kalanie AR. Multiple sclerosis: report on 200 cases from Iran. Mult Scler. 2003;9(1):36-8. doi: 10.1191/1352458503ms887oa. [PubMed: 12617266].
  • 34. Etemadifar M, Sajjadi S, Nasr Z, Firoozeei TS, Abtahi SH, Akbari M, et al. Epidemiology of multiple sclerosis in Iran: a systematic review. Eur Neurol. 2013;70(5-6):356-63. doi: 10.1159/000355140. [PubMed: 24192707].
  • 35. Torabipour A, Asl ZA, Majdinasab N, Ghasemzadeh R, Tabesh H, Arab M. A study on the direct and indirect costs of multiple sclerosis based on expanded disability status scale score in khuzestan, iran. Int J Prev Med. 2014;5(9):1131-8. [PubMed: 25317296].
  • 36. Rezaali S, Khalilnezhad A, Naser Moghadasi A, Chaibakhsh S, Sahraian MA. Epidemiology of multiple sclerosis in Qom: Demographic study in Iran. Iran J Neurol. 2013;12(4):136-43. [PubMed: 24250923].
  • 37. Kobelt G, Berg J, Lindgren P, Gerfin A, Lutz J. Costs and quality of life of multiple sclerosis in Switzerland. Eur J Health Econ. 2006;7 Suppl 2:S86-95. doi: 10.1007/s10198-006-0383-9. [PubMed: 17310338].
  • 38. Silva AM, Bettencourt A, Pereira C, Santos E, Carvalho C, Mendonca D, et al. Protective role of the HLA-A*02 allele in Portuguese patients with multiple sclerosis. Mult Scler. 2009;15(6):771-4. doi: 10.1177/1352458509104588. [PubMed: 19482867].
  • 39. Bergamaschi L, Leone MA, Fasano ME, Guerini FR, Ferrante D, Bolognesi E, et al. HLA-class I markers and multiple sclerosis susceptibility in the Italian population. Genes Immun. 2010;11(2):173-80. doi: 10.1038/gene.2009.101. [PubMed: 19907433].
  • 40. Fogdell-Hahn A, Ligers A, Gronning M, Hillert J, Olerup O. Multiple sclerosis: a modifying influence of HLA class I genes in an HLA class II associated autoimmune disease. Tissue Antigens. 2000;55(2):140-8. [PubMed: 10746785].
  • 41. Bergamaschi L, Ban M, Barizzone N, Leone MA, Ferrante D, Fasano ME, et al. Association of HLA class I markers with multiple sclerosis in the Italian and UK population: evidence of two independent protective effects. J Med Gene. 2011:jmg. 2010.080721.
  • 42. Isobe N, Gourraud PA, Harbo HF, Caillier SJ, Santaniello A, Khankhanian P, et al. Genetic risk variants in African Americans with multiple sclerosis. Neurology. 2013;81(3):219-27. doi: 10.1212/WNL.0b013e31829bfe2f. [PubMed: 23771490].
  • 43. Kalanie H, Kamgooyan M, Sadeghian H, Kalanie AR. Histocompatibility antigen (HLA) associations with multiple sclerosis in Iran. Mult Scler. 2000;6(5):317-9. doi: 10.1177/135245850000600504. [PubMed: 11064440].
  • 44. Zabihi A, Ebrahimi H, Rashidfarrokhi F, Ramazani A. Investigating the relationship between MS disease and its symptoms and class I leukocyte antigens in Kerman city. 2005.
  • 45. Lotfi J, Nikbin B, Derakhshan I, Aghai Z, Ala F. Histocompatibility antigens (HLA) in multiple sclerosis in Iran. J Neurol Neurosurg Psychiatry. 1978;41(8):699-701. [PubMed: 681957].
  • 46. Ramadan MA, Ali IR, Mohamed DH, Abboud H, El Gendy W. Study of the association between the human leukocyte antigen class i molecules and remitting relapsing multiple sclerosis ms. Bull Alex Fac Med. 2008;44(4).

Featured Image:

Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments